Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
NCT05533632 on ClinicalTrials.gov · last registry update 2025-09-24
Finished 18 January 2024, after enrolling 104 people. Primary outcome, as filed: Number of Adverse Events (AEs). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 104
- Started
- 2022-04-25
- Primary completion
- 2024-01-18 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Adverse Events (AEs)
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.